|
Wednesday, January 18, 2023, San Francisco, California, 7:15 PM – 9:15 PM Pacific Time (10:15 PM – 12:15 AM Eastern Time)
Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Colorectal CancerPart 1 of a 3-Part CME Symposium Series Held in Conjunction with the 2023 ASCO Gastrointestinal Cancers Symposium
Location
San Francisco Marriott Marquis 780 Mission Street San Francisco, CA 94103 Hotel Phone: (415) 896-1600 Program Schedule — Pacific Time 7:00 PM – 7:15 PM — Registration 7:15 PM – 9:15 PM — Educational Dinner Meeting Meeting Room Golden Gate Ballroom — Salon A (B2 Level) This event will also be webcast live. Please see Registration tab for details. Faculty
Tanios Bekaii-Saab, MD Professor, Mayo Clinic College of Medicine and Science Program Leader, Gastrointestinal Cancer Mayo Clinic Cancer Center Consultant, Mayo Clinic in Arizona Chair, ACCRU Research Consortium Phoenix, Arizona Scott Kopetz, MD, PhD Professor and Deputy Chair Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston, Texas John Strickler, MD Associate Professor Duke University Durham, North Carolina Eric Van Cutsem, MD, PhD Professor of Medicine Digestive Oncology University Hospitals Leuven Leuven, Belgium Moderator Kristen K Ciombor, MD, MSCI Associate Professor of Medicine Division of Hematology/Oncology Vanderbilt-Ingram Cancer Center Nashville, Tennessee This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Exelixis Inc, Lilly, Natera Inc, and Seagen Inc.
Program Schedule — Pacific Time
7:00 PM – 7:15 PM — Registration 7:15 PM – 9:15 PM — Educational Dinner Meeting MODULE 1: Integration of Therapies Targeting BRAF and HER2 in Metastatic Colorectal Cancer (mCRC) — Dr Strickler
MODULE 2: Optimizing the Use of Immune Checkpoint Inhibitors in the Management of mCRC — Dr Ciombor
MODULE 3: Evidence-Based Selection and Sequencing of Therapy for Patients with mCRC — Prof Van Cutsem
MODULE 4: Promising Agents and Strategies for Patients with mCRC — Dr Bekaii-Saab
MODULE 5: The Changing Management Paradigm for Localized CRC — Dr Kopetz
Target Audience
CME Credit Form FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Bekaii-Saab — Consulting Agreements (to Institution): Arcus Biosciences, Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Merck KgaA, Merus BV, Pfizer Inc, Seagen Inc; Consulting Agreements (to Self): AbbVie Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Boehringer Ingelheim Pharmaceuticals Inc, Caladrius Biosciences, Celularity, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, Exact Sciences, Foundation Medicine, Illumina, Janssen Biotech Inc, Kanaph Therapeutics, MJH Life Sciences, Natera Inc, Swedish Orphan Biovitrum AB, Stemline Therapeutics Inc, Treos Bio; Data and Safety Monitoring Board/Committee: 1Globe Health Institute, AstraZeneca Pharmaceuticals LP, Eisai Inc, Exelixis Inc, FibroGen Inc, Merck, Suzhou Kintor; Inventions/Patents: WO/2018/183488 licensed to Imugene, WO/2019/055687 licensed to Recursion; Research Funding (to Institution): AbGenomics, Agios Pharmaceuticals Inc, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Atreca, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merus BV, Mirati Therapeutics, Novartis, Pfizer Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc; Scientific Advisory Board: Artiva Biotherapeutics Inc, Immuneering Corporation, Imugene, Replimune, Sun Biopharma, Xilis; Nonrelevant Financial Relationship: Pancreatic Cancer Action Network. Dr Kopetz — Consulting Agreements: AbbVie Inc, Amal Therapeutics SA, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bicara Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Carina Biotech, Daiichi Sankyo Inc, EMD Serono Inc, Endeavor Biomedicines, Flame Biosciences, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, HalioDx, Holy Stone Healthcare Co Ltd, Inivata, Ipsen Biopharmaceuticals Inc, Iylon Precision Oncology, Jacobio Pharmaceuticals Group Co Ltd, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Lilly, Lutris Pharma, Merck, Mirati Therapeutics Inc, Natera Inc, Novartis, Numab, Pfizer Inc, Pierre Fabre, Redx Pharma Plc, Repare Therapeutics, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Xilis. Dr Strickler — Advisory Committee: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, GlaxoSmithKline, Lilly, Natera Inc, Pfizer Inc, Pionyr Immunotherapeutics, Seagen Inc, Silverback Therapeutics, Takeda Pharmaceuticals USA Inc, Viatris; Consulting Agreement: Zentalis Pharmaceuticals; Contracted Research: AbbVie Inc, Amgen Inc, Bayer HealthCare Pharmaceuticals, Curegenix, Daiichi Sankyo Inc, Erasca, Genentech, a member of the Roche Group, Gossamer Bio, Leap Therapeutics Inc, Lilly, Nektar, Sanofi, Seagen Inc, Silverback Therapeutics; Data and Safety Monitoring Board/Committee: AbbVie Inc, BeiGene Ltd, Pionyr Immunotherapeutics; Nonrelevant Financial Relationship: AStar D3. Prof Van Cutsem — Advisory Committee: AbbVie Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biocartis, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, GlaxoSmithKline, Halozyme Inc, Helsinn Healthcare SA, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck KGaA, Merck Sharp & Dohme Corp, Mirati Therapeutics Inc, Novartis, Pierre Fabre, Roche Laboratories Inc, Seagen Inc, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Taiho Oncology Inc, Terumo Medical Corporation, TRIGR (trial), Zymeworks Inc; Research Grants to Institution: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck KGaA, Merck Sharp & Dohme Corp, Novartis, Roche Laboratories Inc, Servier Pharmaceuticals LLC.MODERATOR — Kristen K Ciombor, MD, MSCI – Advisory Committee and Consulting Agreements: AbbVie Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Phar Incyte Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Personalis Inc, Pfizer Inc, Replimune, Seagen Inc; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Incyte Corporation, Merck, NuCana, Pfizer Inc, Seagen Inc. Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Exelixis Inc, Lilly, Natera Inc, and Seagen Inc. San Francisco Marriott Marquis
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers. IN-PERSON registration for clinicians in practice/healthcare professionals
Thank you for your interest in our CME program. At this time online preregistration is closed for this in-person event. SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 6:45 PM PST on Wednesday, January 18th. If you are interested in attending, please visit our registration desk outside the Gold Gate Ballroom – Salon A (B2 Level) of the San Francisco Marriott Marquis hotel (780 Mission Street) within walking distance of the Moscone Convention Center (2 street blocks).
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153. NOTICE: Registration for this event is independent of registration for the 2023 ASCO GI Symposium. LIVE WEBCAST registration for all professionals
Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. REGISTRATION FOR WEBCAST »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
Not official events of the 2023 ASCO Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation. |